Executive Summary: Haemonetics’ Strong Start to Fiscal 2027
Haemonetics Corporation (NYSE: HAE) delivered a robust performance for the first quarter of fiscal 2027, driven by broad-based execution across its core business segments. The medical technology company demonstrated significant commercial momentum, prompting management to raise its full-year organic revenue growth guidance to a range of 4% to 7%. This quarter represents the first reporting period under the company’s newly implemented reportable segment structure, which was established in June 2026 to optimize operational efficiency and strategic focus.
Key Performance Drivers: MedSurg, Plasma, and Vascular Closure
The company’s positive quarterly results were underpinned by strong execution across all three primary product platforms. The MedSurg business has successfully reemerged as a sustainable, long-term growth driver, complementing the durable performance of the Apheresis segment.
- Plasma Revenue & Persona PLUS: Plasma revenue grew by 8% during the quarter, driven by market share gains and healthy collection volumes. This growth successfully offset historical customer losses and divestiture headwinds from the prior year. The rollout of the Persona PLUS collection platform is running ahead of schedule. Early adopters of the integrated system are reporting yield improvements exceeding 5%, highlighting the efficiency gains of the new technology.
- Vascular Closure Recovery: The Vascular Closure franchise achieved double-digit revenue growth, outperforming the broader market. This acceleration was supported by the stabilization of Pulsed Field Ablation (PFA) procedures at approximately 80% to 85% penetration, which has normalized access site growth to a rate of 6% to 7%. Commercial adoption was further aided by the expanded label indication for the VASCADE MVP XL system in large-bore procedures.
- Hemostasis Management: The segment recorded durable mid-teens growth in consumables, driven by increased clinical utilization and the ongoing global launch of the heparinase neutralization cartridge.
Fiscal 2027 Financial Outlook and Assumptions
Normalizing for prior-year software benefits, Haemonetics is beginning to realize structural operating leverage from its historical investments in manufacturing and logistics. Management expects adjusted operating margin expansion of 50 to 100 basis points for the full fiscal year, supported by favorable product mix and Persona PLUS adoption.
However, the guidance remains balanced due to anticipated macroeconomic headwinds. Management assumes conservative plasma collection volume growth of 0% to 2%, despite current market trends tracking in the high single to low-double digits. Additionally, while the company anticipates receiving a $7 million tariff refund in the second quarter, this tailwind is expected to be offset by rising oil prices and persistent material inflation later in the fiscal year. Pipeline milestones for the remainder of the year include the expected U.S. launch of the PerQseal Elite system and label expansions in Japan.
Capital Allocation and Balance Sheet Management
Haemonetics demonstrated strong financial discipline, generating free cash flow conversion equal to 75% of adjusted net income during a seasonally weak quarter. This cash generation was driven by tight working capital management and lower capital expenditure outlays for device placements. Management prioritized debt reduction, repaying $100 million of the outstanding balance on its revolving credit facility. Future capital allocation will prioritize organic growth, debt repayment, and opportunistic share repurchases under the remaining $325 million authorization, with management stating that M&A is currently paused.
Frequently Asked Questions (FAQ)
What is driving the updated organic revenue growth guidance for Haemonetics?
Management raised the organic revenue growth guidance for fiscal 2027 to 4% to 7% due to Q1 outperformance, accelerated adoption of the Persona PLUS platform, and double-digit growth in the Vascular Closure segment.
How is the adoption of Pulsed Field Ablation (PFA) affecting the Vascular Closure business?
PFA procedure penetration has stabilized at 80% to 85%, which has normalized access site growth to 6% to 7%. This stabilization, combined with the VASCADE MVP XL label expansion, has allowed Haemonetics to capture market share and return to double-digit growth.
What are the company’s capital allocation priorities for the rest of fiscal 2027?
The company is prioritizing organic growth initiatives and debt reduction, highlighted by the recent $100 million paydown on its revolving credit facility. Opportunistic share repurchases under the remaining $325 million authorization remain an option, while M&A activity is temporarily paused.
